Europäische Union - Deutsch - EMA (European Medicines Agency)

mylan ireland limited - sitagliptin hydrochloride monohydrate, metformin hydrochloride - diabetes mellitus, typ 2 - drogen bei diabetes verwendet - for adult patients with type 2 diabetes mellitus:sitagliptin/metformin hydrochloride mylan is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin. sitagliptin/metformin hydrochloride mylan is indicated in combination with a sulphonylurea (i. , dreifach-kombinationstherapie) als ergänzung zu diät und bewegung bei patienten, die unzureichend kontrolliert auf ihren maximalen tolerierten dosis von metformin und sulphonylurea. sitagliptin/metformin hydrochloride mylan is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (pparg) agonist (i. , a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a pparg agonist. sitagliptin/metformin hydrochloride mylan is also indicated as add-on to insulin (i. , triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.

Belgien - Deutsch - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

mylan - venlafaxine hydrochloride - hartkapsel, retardiert - 37,5 mg - venlafaxine hydrochloride 42.42 mg - venlafaxine

Belgien - Deutsch - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

mylan - venlafaxine hydrochloride - hartkapsel, retardiert - 75 mg - venlafaxine hydrochloride 84.85 mg - venlafaxine

Belgien - Deutsch - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

mylan - venlafaxine hydrochloride - hartkapsel, retardiert - 150 mg - venlafaxine hydrochloride 169.7 mg - venlafaxine

Belgien - Deutsch - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

v.m.d. - xylazine hydrochloride - injektionslösung - 2 % - xylazine hydrochloride 23.32 mg/ml - xylazine - rind; hund; pferd; katze

Europäische Union - Deutsch - EMA (European Medicines Agency)

bayer ag - finerenone - renal insufficiency, chronic; diabetes mellitus, type 2 - wirkstoffe, die auf das renin-angiotensin-system einwirken - kerendia is indicated for the treatment of chronic kidney disease (stage 3 and 4 with albuminuria) associated with type 2 diabetes in adults.

Europäische Union - Deutsch - EMA (European Medicines Agency)

les laboratoires servier - trifluridine, tipiracil hydrochloride - kolorektale neoplasmen - antineoplastische mittel - colorectal cancerlonsurf is indicated in combination with bevacizumab for the treatment of adult patients with metastatic colorectal cancer (crc) who have received two prior anticancer treatment regimens including fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapies, anti-vegf agents, and/or anti-egfr agents. lonsurf is indicated as monotherapy for the treatment of adult patients with metastatic colorectal cancer (crc) who have been previously treated with, or are not considered candidates for, available therapies including fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapies, anti-vegf agents, and anti egfr agentsgastric cancerlonsurf is indicated as monotherapy for the treatment of adult patients with metastatic gastric cancer including adenocarcinoma of the gastroesophageal junction, who have been previously treated with at least two prior systemic treatment regimens for advanced disease.

Europäische Union - Deutsch - EMA (European Medicines Agency)

mylan pharmaceuticals limited - anagrelide hydrochloride - thrombozythämie, wesentlich - antineoplastische mittel - anagrelide ist indiziert zur verringerung der erhöhten thrombozytenzahl in gefahr, wesentliche thrombocythaemia (et) patienten, die intolerant sind, um ihre derzeitige therapie oder deren erhöhte thrombozytenzahl sind nicht auf ein vertretbares maß reduziert, die durch ihre derzeitige therapie. an at-risk patientan at-risk essential thrombocythaemia patient is defined by one or more of the following features:>60 years of age ora platelet count >1,000 x 10⁹/l ora history of thrombo-haemorrhagic events.

Deutschland - Deutsch - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

mibe gmbh arzneimittel (8004658) - hydrochlorothiazid; triamteren; propranololhydrochlorid - tablette - teil 1 - tablette; hydrochlorothiazid (00512) 12,5 milligramm; triamteren (05876) 25 milligramm; propranololhydrochlorid (07597) 80 milligramm

Deutschland - Deutsch - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

carinopharm gmbh (8031371) - dexamethasonacetat (ph.eur.); lidocainhydrochlorid 1 h<2>o - kristallsuspension - dexamethasonacetat (ph.eur.) (02286) 10 milligramm; lidocainhydrochlorid 1 h<2>o (01693) 60 milligramm